-
A Glimpse of the Oncology Drug Treatment Market in China
PharmaSources/Xiaoyaowan
May 31, 2021
According to statistics, the market size of China’s oncology treatment industry reached RMB387.6 billion in 2020, with a compound annual growth rate of 10.3% in the past five years as compared to RMB261.4 billion in 2016, and this market size is expected
-
With Anlotinib Sold over RMB4 Billion in 2020, Which will be the Next Blockbuster of Sino Biopharmaceutical?
PharmaSources/Caicai
May 31, 2021
Sino Biopharmaceutical has recently released its 2020 annual results, with total revenue of RMB23.647 billion, down 2.4% year on year, net profit attributable to the parent of RMB2.771 billion, up 0.3% year on year
-
Immune Drug Combination Therapies for Liver Cancer: Analysis of the Clinical Studies of the Two Approved and Two First-line Drug Combinations
PharmaSources/Yuntian
May 31, 2021
Liver cancer has recently drawn much attention by a Chinese movie star Ng Man-tat who died of liver cancer and the National Liver Day on Mar. 18.
-
Pride of New Chinese Medicine, Icaritin To Be Included in the Priority Review as the First-line Treatment for Hepatocellular
PharmaSources/Dopine
May 25, 2021
CDE official website recently disclosed that the marketing application of the Category 1.2 innovative traditional Chinese medicine "Icaritin" of Shenogen Pharma Group/Kangerfu Pharmaceutical would be included in the priority review as scheduled
-
Good News in the Chinese Diabetes Field and Several Original Research Drugs Underway
PharmaSources/Dopine
May 25, 2021
Glad tidings came recently in terms of supervision of two domestic diabetes drugs. Semaglutide, Novo Nordisk's blockbuster hypoglycemic drug, advanced to the administrative approval stage (acceptance number: JXSS2000005/6) on April 20.
-
Development of Anticancer Drugs for Ferroptosis: An Analysis of Representative Natural Products
PharmaSources/Yuntian
May 08, 2021
Over the past years, anticancer strategies based on ferroptosis have been well acknowledged, leading to a boom in the development of anticancer drugs at home and abroad.
-
O-drug Approved as First-line Immunotherapy for Gastric Cancer and What Other Domestic Counterparts to Expect
PharmaSources/Yefenghong
May 08, 2021
O-drug is the first approved immunotherapy for first-line treatment of gastric cancer.
-
New Track: Japanese Digital Therapeutics for Hypertension Achieves Success in Phase III Clinical Trial
PharmaSources/Xiaoyaowan
April 07, 2021
The Japanese company CureApp has recently announced the results of a Phase III multicenter randomized controlled clinical trial of their digital therapeutics for hypertension, which was jointly researched by CureApp and a team led ...
-
Breaking News! Chia Tai Tianqing to Receive Approval for another Generic in China
PharmaSources/Caicai
March 26, 2021
The marketing application (acceptance No.: CYHS1900381) of Chia Tai Tianqing’s Class 4 generic drug has recently changed to the “Under approval” status, and the drug is expected to be approved for marketing this month ...
-
A Review of the Export Data of China’s Plant Extract Market in 2020 and Potential Varieties
PharmaSources.com
March 18, 2021
In 2020, the outbreak of the pandemic stimulated consumer demand for naturally sourced plant extracts, however, China’s export value of plant extracts in the first half of 2020 reached USD1.265 billion, up only 1.08% year on year.